Adela Announces $48 Million in Financing and Leadership Addition to Advance Tissue-Agnostic Minimal Residual Disease (MRD) Monitoring Product Portfolio Based on Genome-Wide Methylome Approach

Investors include F-Prime Capital, OrbiMed, Deerfield Management, Decheng Capital, Labcorp and RA Capital Management Proceeds from this financing will be used to advance Adela's technology platform and commercialize Adela's first product for MRD monitor... Diagnostics, Venture Capital Adela Inc, multi-cancer early detection
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news